In pluripotent stem cells, DNA damage triggers loss-of-pluripotency and apoptosis as a safeguard to exclude damaged DNA from the lineage. An intricate DNA damage response (DDR) signaling network ensures that the response is proportional to the severity of the damage. Here, we combined an RNAi screen targeting all kinases, phosphatases, and transcription factors with global transcriptomics and phosphoproteomics to map the DDR in mouse embryonic stem cells treated with the DNA cross linker cisplatin. Networks, derived from canonical pathways shared in all three datasets, were implicated in DNA damage repair, cell cycle and survival, and differentiation. Experimental probing of these networks identified a mode of DNA damage-induced Wnt signaling that limited apoptosis. Silencing or deleting the p53 gene demonstrated that genotoxic stress elicited Wnt signaling in a p53-independent manner. Instead, this response occurred through reduced abundance of Csnk1a1 (CK1α), a kinase that inhibits β-catenin. Altogether, our findings reveal a balance between p53-mediated elimination of stem cells, through lossof-pluripotency and apoptosis, and Wnt signaling that attenuates this response to tune the outcome of the DDR.
introduction DNA damage triggers an intricate signaling network that arrests the cell cycle, activates repair mechanisms, and, if damage is too severe, causes cell death or senescence. This DNA damage response (DDR) is essential for the maintenance of genome integrity either by effective damage repair or by elimination of cells carrying damage that is beyond repair [1] [2] [3] . Genotoxic stress often involves a mixture of structurally distinct DNA lesions. For instance, the anticancer drug cisplatin induces intrastrand and interstrand cross links, which can be corrected by nucleotide excision repair and by proteins involved in the Fanconi anemia pathway [4] [5] [6] . Interstrand cross links stall replication forks and, as a secondary event, lead to double strand breaks that can be repaired by homologous recombination or non-homologous end-joining 7 . Moreover, cisplatin induces oxidative stress causing single strand breaks and base modifications that can be corrected through base excision repair 8 .
The DDR is carefully orchestrated in time and place. Stalled replication forks and double strand breaks trigger activation of the kinases ATR, ATM, and DNA-PK 9 . In turn, these phosphorylate a plethora of DNA repair proteins that localize to repair foci. In the case of DNA double strand breaks, these repair foci are also marked by phosphorylated histone variant H2AX (γH2AX) and p53-binding protein 1 (53BP1) 10 . To coordinate repair with other cellular processes, such as transcription and cell cycle progression, ATR and ATM also phosphorylate substrates that diffuse throughout the nucleus, including the checkpoint kinases Chk1 and Chk2. ATM, ATR, DNA-PK, Chk1, and Chk2 have all been implicated in the activation of p53, a critical transcription factor in the DDR that monitors the extent and duration of damage and activates different transcriptional targets to mediate cell cycle arrest, apoptosis, or senescence 9 .
RNA interference (RNAi) screens in cancer cells have identified regulators of genome stability, double strand break repair, and genotoxic stress-induced apoptosis [11] [12] [13] [14] . Although the DDR is evolutionarily conserved, DDR signaling proteins show developmental specificity, tissue specificity, and oncogenic alterations. For instance, p53 plays a major role in the DDR in somatic cells 9 ; whereas its role in embryonic stem (ES) cells is debated [15] [16] [17] . Additionally, p53 signaling is inactivated in many cancers 9, 15 . Genotoxic stress in pluripotent stem cells can elicit additional cellular responses, including induction of differentiation 2 . Here, we combined RNAi screening, transcriptomics, and phosphoproteomics to unravel the signaling network that mediates the response to cisplatin in ES cells. The diversity of cisplatin-induced lesions is representative of the pleiotropic nature of DNA damage occurring through normal cellular metabolism and exposure to environmental mutagens. Our findings provide a comprehensive overview of the response to such genotoxic stress in pluripotent stem cells and lead to a model in which the response of ES cells to DNA damage is regulated by a balance between signaling networks that either promote survival through Wnt signaling or induce differentiation and apoptosis through p53-dependent signaling.
reSultS

RNAi screen identifies modulators of chemosensitivity in ES cells
We performed an RNAi screen targeting all known kinases, phosphatases, and transcription factors in mouse ES cells. Fluorescence activated cell sorting (FACS) for DNA content or ATP-based viability assays showed 60-70% ES cell death 24 hours after treatment with 10 μM cisplatin, and cell death was prevented by the pan-Caspase inhibitor, z-Val-Ala-DL-Asp-fluoromethylketone (Z-VAD-fmk), indicating that cisplatininduced caspase-dependent apoptosis ( fig. S1A, B ). For the screening protocol, Kif11targeted siRNA served as a transfection efficiency control and siRNA targeting GFP or Lamin A/C served as negative controls. Because the role of p53 in the DDR in ES cells is debated [15] [16] [17] , we tested the effect of p53-targeted siRNA on cisplatin-induced apoptosis. Silencing p53 also rescued cells from cisplatin-induced death; whereas the GFP-targeted or Lamin A/C-targeted siRNAs did not affect viability ( fig. S1C ).
In the primary screen, siRNA SMARTpools silenced 2,351 individual genes, and we compared cell viability following 10 μM cisplatin treatment with the viability of vehicle 
Kinases (20) . Transcr. Factors (22) No effect The SILAC experiment was performed as described previously 20 . In short, we used isotope-labeled amino acids to distinguish between proteins isolated from untreated ES cells and ES cells treated with 5 μM cisplatin for 4 h. Isolated peptide mixtures were enriched for phosphopeptides on a titanium column and samples were analyzed by tandem mass spectrometry ( fig. S2E ). Of the 8,251 identified phosphopeptides, 1,612 (representing 1,025 different proteins) showed differential phosphorylation defined by a ratio less than 0.67 or greater than 1.5 (p<0.05). These included several known targets of ATM or of molecules derived from indicated canonical pathways shared in all three datasets. Serine, threonine and tyrosine residues that showed an increased or decreased phosphorylation state in response to cisplatin are indicated with red and blue, respectively. Red and blue fill indicates that the abundance of the mRNA encoding protein was increased or decreased, respectively, by cisplatin. Red or blue outline indicates that RNAi targeting this node protected or enhanced cisplatin-induced loss of viability. See We generated interaction-enriched networks from the 2,269 differentially expressed genes and from the 1,025 differentially phosphorylated proteins. In concordance with the functional genomics analysis ( Fig. 2A ), canonical pathways involved in DNA repair, cell cycle and survival, and differentiation were overrepresented (table S3) . We focused on canonical pathways that were significantly overrepresented (p<0.05; Fisher's exact test) in all three datasets ( Fig. 2B ). For such shared canonical pathways, the molecules derived from each dataset were combined and imported into IPA® to generate integrated subnetworks. These subnetworks belonged to canonical pathways implicated in DNA damage signaling and repair, such as "ATM Signaling" and "p53 Signaling" and in cell cycle and survival, such as "Cell Cycle Regulation by Chk Proteins" (Fig. 3 ). Additionally, canonical pathways implicated in differentiation were identified, such as "BMP (Bone Morphogenetic Protein) signaling", "RAR (Retinoic Acid Receptor) Activation," and "Wnt Signaling" (Fig. 4 ). The overrepresentation of the canonical pathways "DNA DSB (Double Strand Break) Repair by HR (Homologous Recombination)," "BRCA1 in the DDR," and "ATM Signaling" in the network analysis indicated that DNA DSB repair mechanisms were activated in cisplatin-treated cells (Fig. 2B, Fig. 3 , and table S3 ). Indeed, cisplatin treatment increased the ATM-or ATR-mediated phosphorylation of double strand break response mediators, such as 53BP1, MDC1, and BRCA1, and increased transcription of the gene encoding Rad51, a homologous recombination factor (table S2 and S4) . Moreover, silencing the repair factors BRCA1 or BRCA2 sensitized ES cells to cisplatin (Fig. 1C ).
To evaluate DNA damage repair and recovery, ES cells were exposed to 1 μM or 5 μM of cisplatin for 6 h and, during subsequent recovery for 24 h, we monitored reentry into the cell cycle, the proportion of apoptotic cells, and the number of repair foci marked by 53BP1 ( fig. S3 ). At early timepoints, ES cells arrested and showed repair foci marked by 53BP1, but after 24 h recovery they did not re-enter the cell cycle, foci did not disappear, and a subG0/G1 fraction emerged. This indicated that cell cycle arrest and DNA damage repair attenuated cisplatin-induced apoptosis, but ultimately other DDR components controlled apoptosis proportional to the amount of damage. Notably, we did not identify ATM and ATR in the RNAi screen (Fig. 1C ). Silencing both kinases simultaneously was inefficient ( fig. S4A ) and did not decrease survival or increase cisplatin sensitivity ( fig. S4B ). However, pharmacological inhibition of ATM or ATR activity strongly enhanced cisplatin-induced apoptosis ( fig. S4C ), confirming the critical role for ATM and ATR in the DDR in ES cells, but indicating that a small pool of active ATM or ATR was sufficient for a normal response to cisplatin treatment.
p53 is present in several DDR networks and mediates ES cell apoptosis but not cell cycle arrest
We identified a network centered on p53 ( Fig. 3A and table S4 ) and active pSer15 p53 accumulated in a time-and concentration-dependent manner following treatment with cisplatin ( Fig. 5A, B ). The "ATM Signaling" and the "Cell Cycle Regulation by Chk proteins" networks ( Fig. 3B , C), as well as the "Wnt β-Catenin Signaling" network ( Fig. 4C ), included p53. Of the 621 p53-regulated genes identified with the MetaCore™ data-mining software, 100 overlapped with the 2,269 cisplatin-regulated genes, including genes encoding proapoptotic proteins ( Fig. 5C and table S5 ). In agreement, cisplatin-induced translocation of phosphatidylserine to the outer membrane leaflet, an indicator of apoptotic cells, was p53-dependent ( Fig. 5D ). We also confirmed the central role for p53 in ES cell apoptosis in response to another genotoxic compound, the topoisomerase inhibitor doxorubicin, using transient and stable p53 silencing methods ( Fig. 5E ).
Despite dose-dependent induction of the p53 target gene, p21 (Cdkn1a), encoding a cell cycle inhibitor (table S5; fig S2D) , and presence of p53 in the "Cell Cycle Regulation by Chk Proteins" network ( Fig. 3C ), we did not observe a p53-dependent G1 arrest in response to a sublethal dose of 1 μM cisplatin. Instead, ES cells accumulated in S phase in a p53-independent manner ( Fig. 5F) . A candidate mediator for such accumulation in S phase is E2F4, a transcriptional regulator reported to be implicated in the suppression of genes that promote cell cycle progression in the G2 phase 21 . In line with such a role, silencing E2F4 enhanced cisplatin-induced ES cell death (Fig. 1C ). Genotoxic stress causes altered ES cell self-renewal and differentiation signaling The integrated datasets produced networks associated with self-renewal and differentiation signaling, including "BMP Signaling," "RAR Activation," and "Wnt β-Catenin Signaling," (Fig. 2B and Fig. 4 ). Changes in the BMP signaling network noted in response to cisplatin exposure, including reduced mRNA abundance for the BMP receptor BMPR1A and for Smad4, and the sensitization to cisplatin upon silencing of Smad6 ( Fig. 4) were not reflected by altered BMP signaling in response to cisplatin treatment of HM1 ES cells with a BMP luciferase reporter ( fig. S5A ). Although transforming growth factor β (TGFβ) signaling was not significantly enriched in the three datasets, various proteins in the BMP network can also participate in TGFβ signaling, such as Smad4 and Smad6 22 . Cisplatin treatment significantly suppressed activity of a TGFβ reporter ( fig.  S5B ). However, treatment with TGFβ or an inhibitor of the ALK TGFβ receptors did not affect cisplatin sensitivity in ES cells ( fig. S5C and D), suggesting that neither TGFβ nor BMP signaling have a major role in the ES cell DDR.
We observed signs of decreased pluripotency following cisplatin treatment indicated by time-and concentration-dependent reduction in the mRNA and protein abundance of Nanog, a transcription factor associated with pluripotency ( fig. S6A,B ), but not others such as Oct4 ( fig.S6E ) 23 . In agreement with a previously reported mechanism whereby p53 represses Nanog expression 24 , decreased mRNA abundance of Nanog in response to cisplatin was observed in wild-type, but not in p53-/-ES cells ( fig. S6B ). Such a differentiation response would be expected to increase sensitivity to genotoxic stress, because forced differentiation by removal of leukemia inducible factor (LIF) or addition of retinoic acid (RA) sensitized ES cells to cisplatin-induced apoptosis (fig. S6C, D). Notably, cisplatin did not induce mRNA abundance of known lineage markers (for example, Brachyury) ( fig. S6E ), and the IPA®-predicted "RAR Activation" network was not reflected by a general induction of known RA-regulated differentiation genes ( fig. S6E ).
Thus, alterations in self-renewal and differentiation signaling associated with cisplatin-induced DNA damage were accompanied by a trend towards loss of pluripotency but cisplatin triggered apoptosis before biologically relevant signs of differentiation were evident. 
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DNA damage-induced activation of Wnt signaling is p53-independent
The Wnt/β-catenin pathway is believed to play a critical role in controlling the self-renewal and lineage differentiation of pluripotent stem cells and has been connected to stress responses through p53 [25] [26] [27] . We tested if DNA-damaging agents activated the predicted Wnt β-Catenin signaling network ( Fig. 4C ) in cells transfected with a reporter stimulated by the β-catenin-activated Tcf and Lef transcription factors (Tcf/Lef). The genotoxicants cisplatin and doxorubicin stimulated expression of the Tcf/Lef reporter, but the oxidative agent diethyl-maleate, which depletes cellular glutathione, did not ( Fig. 6A ).
Silencing β-catenin prevented cisplatin-induced Tcf/Lef transcriptional activity ( Fig. 6B ) and sensitized ES cells to cisplatin-mediated loss of viability ( Fig. 6C ). Conversely, cisplatin toxicity was decreased if Wnt signaling was enhanced by cotreatment with the GSK3β inhibitor LiCl ( and Fig. 5D and E) or deleting ( Fig. 6E ) p53 protected against cisplatin-induced loss of viability, it did not affect induction of Wnt signaling by cisplatin ( Fig. 6F and G), indicating that enhanced Wnt signaling occurs independently of and in parallel to p53 signaling. The predicted Wnt β-Catenin signaling network included cisplatin-stimulated increased mRNA abundance for three Wnt ligands, indicating a potential mechanism for enhanced Wnt signaling in response to DNA damage ( Fig. 4 and Fig. 7A and B ). The genes encoding Wnt-8a, -8b, and -9a are transcriptionally induced in response to p53 accumulation 27 . Silencing p53 showed that induction of these Wnt ligands by cisplatin required p53 (Fig.  7B ); whereas enhanced Wnt signaling was p53-independent ( Fig. 6F and G). Silencing these Wnt ligands individually did not affect cisplatin sensitivity ( Fig. 7C ), but silencing all three simultaneously slightly but significantly enhanced cisplatin-induced cell death and suppressed cisplatin-induced Wnt reporter activity ( fig. S7B , C). These findings suggested that an alternative, p53-independent mechanism of enhanced Wnt signaling suppressed the p53-mediated apoptotic response to genotoxic stress in ES cells.
Downregulation of suppressors of Wnt signaling protects against apoptosis
The predicted Wnt signaling network included decreased mRNA abundance of Tcf7L1 and Tcf7L2 in response to cisplatin treatment ( Fig. 4 ). These Tcf family members antagonize Tcf1/Lef1-mediated transcription of Wnt target genes involved in self-renewal 28 . Parenthetically, nomenclature in this network is confusing: Tcf7L1 is also termed Tcf3, but Tcf3 is also another name for E2A, which is also known as Itf1; Tcf7L2 is also termed Tcf4, but Tcf4 is also another name for Itf2. Tcf3 and Tcf4 in the network represent Itf1 and Itf2.The mRNA abundance for Tcf7L1, and to a lesser extent Tcf7L2, was decreased in response to the genotoxicants doxorubicin (Dox), etopside, and cisplatin (CP), and to oxidative agents, such as diethyl maleate (DEM), menadione (MEN), and hydrogen peroxide (H 2 O 2 ) ( Fig. 7A and D). Silencing Tcf7L1 but not Tcf7L2, enhanced cisplatininduced Wnt signaling ( Fig. 7E ) but, in agreement with the RNAi screen, silencing Tcf1, Tcf7L1, Tcf7L2, or Lef1 did not affect cisplatin-induced cell death ( Fig. 7F ). Therefore, we explored the role of proteins within the predicted Wnt β-Catenin signaling network that were identified in the RNAi screen and act upstream of Tcf1/ Lef1-mediated transcription of Wnt target genes. These included Csnk1a1 (CK1α), a suppressor of Wnt/β-catenin signaling [29] [30] [31] and the phosphatases Ppp2r1a and Ppp2ca that promote Wnt signaling by dephosphorylation of β-catenin or Axin 32, 33 (Fig. 4C) .
Silencing Ppp2r1a or Ppp2ca enhanced cisplatin-, doxorubicin-, or UV-induced ES cell death ( Fig. 1C and Fig. 8A ) and suppressed cisplatin-induced Wnt activation ( Fig. 8B ), in agreement with their role in Wnt-mediated pro-survival signaling. Because we had no evidence for transcriptional or posttranslational regulation of these genes in response to cisplatin treatment ( Fig. 4C ), we focused on Csnk1a1. Transient or stable silencing of Csnk1a1 protected against cisplatin-induced loss of viability and apoptosis ( Fig. 1C and 8A, fig. S8, and fig. S9A and B) and stimulated Wnt signaling ( Fig. 8B  and fig. S9C ). The protection against cisplatin-induced cytotoxicity and the enhanced cisplatin-mediated Wnt signaling in response to Csnk1a1 silencing were blocked by simultaneously silencing β-catenin ( Fig. 8C and D) . Although Csnk1a1 controlled the apoptotic response to cisplatin, it did not play a role in cisplatin-induced cell cycle arrest ( Fig. 8E ). Moreover, silencing Csnk1a1 did not affect p53 activation in response to cisplatin ( Fig. 8F ).
Transcriptomics and phosphoproteomics suggested that Csnk1a1 was regulated at the transcriptional and posttranslational levels in response to cisplatin treatment. Csnk1a1 mRNA abundance was decreased in response to cisplatin and other genotoxicants (Fig. 7A , D and Fig. 8G ,H); whereas oxidative agents H 2 O 2 or menadione increased its expression ( Fig. 7A and D) . The reduction of Csnk1a1 mRNA was accompanied by a decreased abundance of Csnk1a1 protein after 12 hours of cisplatin treatment (Fig. 8I ). Moreover, 4 hours after treatment, phosphorylation of Csnk1a1 at Ser3, a residue within a predicted GSK3 recognition motif, was reduced ( Fig. 4 and table S2 ). In agreement with our finding that cisplatin-induced Wnt signaling is p53-independent ( Fig. 6F and G), neither transient silencing nor deletion of the p53 gene affected Csnk1a1 downregulation in response to cisplatin treatment ( Fig. 8G ,H). Consistent with a role for reduced Csnk1a1 activity in cisplatin-induced Wnt signaling, cisplatin treatment led to reduced phosphorylation of β-catenin at Ser45, a CK1 target that marks β-catenin for degradation 34 (Fig. 8I ). Csnk1a1 silencing confirmed that β-catenin Ser45 phosphorylation required Csnk1a1, whereas the knockdown of Csnk1a1 did not affect the total pool of β-catenin, comprising both membrane localized and cytoplasmic fractions ( Fig. 8J ).
As an alternative to Csnk1a1 directly targeting β-catenin, the Wnt signaling network also predicted loss of negative regulation of Wnt signaling through reduced abundance of NDRG1 and reduced phosphorylation of at Ser336 in a predicted Csnk1a1 recognition motif 35 (Fig. 4C and table S2,S4). NDRG1 inhibits Wnt signaling through its interaction with the Wnt receptor LRP6, causing a block in Wnt-induced phosphorylation of LRP6 at Ser1490 36 . Indeed, the latter phosphorylation was significantly induced in ES cells following DNA damage ( Fig. 4C and table S2 ). However, knockdown of NDRG1 affected neither cisplatin-induced loss of viability nor cisplatin-mediated Wnt signaling (fig. S10). Therefore, enhanced Wnt signaling through downregulation of Csnk1a1 in response to genotoxic stress is most likely due to reduced Csnk1a1-mediated -catenin Ser45 phosphorylation ( Fig. 8K ).
diScuSSion
Here, a systems biology approach was used to derive a comprehensive overview of cisplatin-induced DDR signaling in ES cells. Analysis of early protein phosphorylation responses followed by subsequent transcriptional changes was combined with identification of key kinases, phosphatases, and transcription factors that regulate the apoptotic response to cisplatin treatment. Integration of molecules from canonical pathways that were significantly enriched in the RNAi, transcriptomics, and SILAC datasets produced predicted DDR signaling networks. These networks are implicated in pathways regulating DNA damage repair, cell cycle, and apoptosis, as well as selfrenewal and differentiation. In contrast to its role in somatic cells, p53-mediated apoptosis in ES cells is controversial [15] [16] [17] . p53 is a key regulator of various branches of the DDR and the p53target genes that we identified as regulated by cisplatin are implicated in cell cycle arrest (Btg2, Cdc25A), DNA repair (Rad51), and autophagy (DRAM1) [37] [38] [39] . Despite the induction of the p53 target gene p21 (Cdkn1a), an inhibitor of cell cycle progression through G1, we found that ES cells did not undergo G1 arrest in response to DNA damage. Instead, upon treatment with cisplatin, ES cells accumulated in S phase in a p53-independent manner. This S phase arrest may be mediated by E2F4, which is present in the predicted network "Cell Cycle Regulation by Chk proteins". E2F4 is a member of the DREAM transcription repressor complex that represses cell cycle genes and can protect cancer cells against irradiation by maintaining G2 arrest 21 . In ES cells, E2F4 may play a similar role, because silencing E2F4 sensitized cells to cisplatin ( Fig. 8K , table S1). Together, our findings indicate that despite the broad range of p53 target genes that is induced after cisplatin treatment, the critical role of p53 in the DDR in ES cells is to trigger apoptosis upon severe DNA damage.
Activation of p53 reduces the abundance of Nanog 24 and induces Wnt signaling 27 . Counterintuitively; this would implicate p53 in differentiation through the reduction in Nanog, as well as in maintenance of pluripotency through Wnt signaling, in ES cells experiencing genotoxic stress. Our experiments confirmed the role for p53 in reduced expression of Nanog but not in stimulation of Wnt signaling. Although we observe p53-dependent induction of Wnt ligands in ES cells upon genotoxic stress as described 27 , p53 silencing or deletion indicated that genotoxic stress activates Tcf/ Lef-mediated transcription through a p53-independent mechanism. Thus, we propose an alternative model ( Fig. 8K ) in which genotoxic stress triggers opposing signaling pathways, one promoting apoptosis and loss of pluripotency through p53 activation, and the other inhibiting apoptosis through a parallel, p53-independent induction of Wnt/ β-catenin signaling.
Enhanced Wnt signaling can be mediated by increased expression of Wnt ligands; alterations in the balance between activating and inhibitory members of the Tcf family of transcription factors; or stronger signaling from the Frizzled and LRP receptor complex, leading to destabilization of the β-catenin destruction complex in response to Wnt 40 . We found that DNA damage-induced Wnt signaling occurred through reduced activity of several suppressors of the Wnt pathway. These included two members of the Tcf family, Tcf7L1 and Tcf7L2, that suppress Tcf1/Lef1-mediated transcription of Wnt target genes 28 . In addition, three regulators of the β-catenin destruction complex, the phosphatases Ppp2r1a and Ppp2ca, which dephosphorylate β-catenin or Axin 32, 33 , and the kinase Csnk1a1, which promotes β-catenin degradation 31 , participated in the regulation of Wnt signaling in ES cells by DNA damage. Despite the substantially reduced abundance of Tcf7L1 and Tcf7L2 in response to genotoxic and oxidative stress, the roles of these Wnt signaling antagonists appeared modest or they might be functionally redundant because their silencing did not affect the sensitivity of ES cells to cisplatin. Although silencing Ppp2r1a or Ppp2ca strongly suppressed Wnt signaling and sensitized ES cells to cisplatin treatment, the role of these phosphatases in the DDR currently remains unclear because we did not observe transcriptional or posttranscriptional alterations in their abundance or activity in response to cisplatin.
We identified Csnk1a1 as a kinase that fulfilled all criteria of a critical mediator of the genotoxic stress-induced Wnt signaling that antagonized p53-mediated apoptosis in ES cells. Silencing of Csnk1a1 augmented basal and cisplatin-induced Wnt signaling and reduced cisplatin-induced apoptosis. In addition to decreased phosphorylation in a predicted GSK3 recognition motif (an event for which the functional consequence is not known), Csnk1a1 mRNA expression and protein abundance were reduced upon DNA damage. Importantly, this downregulation occurred in a p53-independent fashion, indicating that enhanced Wnt signaling through Csnk1a1 downregulation represents a protective response in ES cells that attenuates p53-mediated apoptosis. The integrated Wnt β-Catenin signaling network pointed to two possible modes of action for this pathway, culminating in β-catenin stabilization: (i) reduced Csnk1a1-mediated phosphorylation of β-catenin at Ser45, an event that marks β-catenin for degradation and (ii) reduced Csnk1a1-mediated phosphorylation of NDRG1, a negative regulator of LRP6-mediated Wnt signaling. Our observations of (i) increased β-catenin Ser45 phosphorylation in response to cisplatin treatment and (ii) a lack of effect of NDRG1 silencing on cisplatininduced Tcf/Lef activity or loss of viability, supports the former model. Finally, a model in which p53-independent induction of Wnt attenuates DNA damage-induced apoptosis implies that Wnt signaling could act as a protective response to chemo-or radiotherapy in cancer and cancer stem cells, where mutations causing p53 inactivation are frequent. Interestingly, Csnk1a1 has recently been identified as a tumor suppressor gene in certain cancer types 31, 41 . Our results indicate that loss of functional Csnk1a1 in cancer may well contribute to chemo-or radioresistance.
RNAi screening
For primary screens, SMARTpool siGENOME libraries targeting all known mouse kinases, phosphatases, and transcription factors were used (ThermoFisher Scientific). For deconvolution confirmation screens, customized libraries containing 4 individual siRNAs targeting each selected mRNA were used (ThermoFisher Scientific). GFP, Lamin A/C, and RISC-free control siRNAs were used according to MIARE guidelines 45 . Kif11 siRNA was used as transfection efficiency control. The siRNA screens were performed on a Biomek FX (Beckman Coulter) liquid handling system. 50 nM siRNA was transfected in 96-well plates using Dharmafect1 transfection reagent (ThermoFisher Scientific). The medium was refreshed every 24 h and cells were exposed to indicated compounds or vehicle controls 64 h post-transfection for 24 h. Primary screens were performed in duplicate and deconvolution screens were performed in quadruplicate. Cell viability assays using ATPlite 1Step kit (Perkin Elmer) were performed according to the manufacturer's instructions followed by luminescence measurement on a plate reader.
RNAi screen data analysis
As a quality control, Z'-factors were determined for each plate, using wells containing cells transfected with siRNA targeting Lamin A/C as a negative control and wells containing cells transfected with siRNA targeting p53 as a positive control 18 . As additional negative controls, mock transfected cells only treated with transfection reagent as well as cells transfected with siRNA not recognized by the RISC complex, non-targeting siRNA, or siRNA targeting GFP were included in each plate. To rank the results, Z-scores for each plate of siRNA-treated cells were calculated using as a reference (i) the mean of all test samples in the primary screen and (ii) the mean of the negative control samples in the secondary deconvolution screen (in order to prevent bias due to pre-enrichment of hits) 19 . Hit determination was done using Z-scores with a cut off value of 1.5 below or above the reference and p-value lower than 0.05.
Transcriptomics analysis
HM1 ES cells were treated with cisplatin (1 μM, 5 μM, or 10 μM) or vehicle control for 8 hours in three independent experiments. B4418 ES cells were treated for 8 hours with the genotoxicants cisplatin, doxorubicin, or etoposide, or the oxidative agents menadione, DEM, or H 2 O 2 . Total RNA was isolated using the RNAeasy kit (Qiagen) according to manufacturer's instructions. RNA quality and integrity was assessed with Agilent 2100 Bioanalyzer system (Agilent technologies). Gene expression was measured using Affimetrix MG430 PM Array plates. All raw data passed the affimetrix quality criteria. Normalization of raw data using the robust multi-array average algorithm and statistical analysis was performed using BRBarray tools (http://linus.nci.nih.gov/BRB-ArrayTools. html). Data are shown as heat maps, in which mRNA abundance was calculated using the Multi Experiment Viewer, using a 0 to 3 scale to indicate relative mRNA abundance. If there are no expression changes, the value is 1.
Phosphoproteomics analysis
The experiment analyzing global phosphoproteomics in cisplatin-treated ES cells is published elsewhere and we refer to this for raw data and details on data analysis procedures 20 . In short, SILAC labeling, isolation, and purification of phosphopeptides was performed according to published procedures 46 and analyzed by tandem mass spectrometry.
Bioinformatics analysis of hits derived from the three datasets
One-step interacting molecules were assigned to hits from the RNAi screen and to differentially expressed genes and differentially phosphorylated proteins using IPA® (Ingenuity Pathway Analysis -Ingenuity Systems). Generation of networks from these interaction-enriched datasets and grouping in canonical pathways was performed in IPA®. Panther classification system was used to assign aliases and activities to genes. Transcription factor targets were identified using MetaCore™ data-mining software (GeneGo Technology).
Apoptosis and cell cycle analysis
For apoptosis analysis, cells were exposed to vehicle or cisplatin for 24 h at which point both floating and attached cells were pooled and fixed in 80% ethanol overnight. Cells were stained using PBS EDTA containing 7.5 mM propidium iodide and 40 mg/ ml RNAseA and measured by flow cytometry (FACSCanto II; Becton Dickinson). The amount of apoptotic cells (sub G0/G1) was calculated using the BD FACSDiva software. As an alternative method to determine apoptosis, phosphatidylserine exposure at the outer membrane leaflet was detected by Annexin V-FITC labeling in real time in attached cells as described previously 47 .
For cell cycle analysis, cells were labeled for 1 h with 10 μM 5-ethynyl-2′deoxyuridine (EdU) either for 1 h before treatment with 1 μM or 5 μM cisplatin or the solvent control for 24 h (pre-labeling), or EdU labeled for 30 min after a 24 h treatment with 1 μM or 5 μM cisplatin (post-labeling). Cells were collected and EdU was detected using Click-iT Alexa 488 and DNA was stained using FxCycle™ Far Red stain (Invitrogen) according to the manufacturer's protocol.
Western blot analysis
Total extracts were prepared in SDS protein lysis sample buffer and boiled for 5 min at 95°C. Extracts were separated by SDS-PAGE on polyacrylamide gels, transferred to PVDF membranes, and membranes were blocked in Tris-Buffered Saline Tween-20 with 5% bovine serum albumin. Membranes were incubated overnight at 4°C with antibodies against p53 (rabbit), p-Ser15 p53 (rabbit), p-Ser45 β-catenin (rabbit), tubulin (mouse), active β-catenin (mouse) or Csnk1a1 (goat) in a dilution of 1:1000, followed by incubation for 1 hour with goat anti rabbit, goat anti mouse or donkey anti goat HRP-conjugated secondary antibodies in a dilution of 1:2500 or Cy-3-conjugated secondary antibodies in a dilution of 1:1000. Chemiluminescence or fluorescence signal was detected using a Typhoon™ 9400 from GE Healthcare.
Immunofluorescence
Cells were plated in μClear 96-well plates (GREINER) coated with 1% gelatin and exposed to vehicle (PBS) or 5 μM cisplatin for indicated times. Cells were fixed in 4% paraformaldehyde followed by 1.5 hours incubation with 53BP1 (rabbit) in a dilution of 1:100 or p-Ser15 p53 (rabbit) in a dilution of 1:1000 and subsequent incubation with Alexa 488-conjugated goat anti rabbit secondary antibodies, which was combined with Hoechst nuclear staining. Actin staining was performed using Rhodamine (tetramethylrhodamine) conjugated Phalloidin (1:1000) for 1 hour. Images were captured using a Nikon TE2000 EPI microscope.
qPCR
RNA was extracted using RNeasy Plus Mini Kit from Qiagen. cDNA was made from 50 ng total RNA with RevertAid H minus First strand cDNA synthesis kit (Fermentas),and real-time qPCR was subsequently performed in triplicate using SYBR green PCR (Applied Biosystems) on a 7900HT fast real-time PCR system (Applied Biosystems). The following qPCR primer sets were used: Gapdh, forward (fw) 5'TCCATGACAACTTTGGCATTG3', reverse (rev) 5'TCACGCCACAGCTTTCCA3'; Atm,fw 5'AACAAAGTCTTAGTGATACTGACCAGAGTTT3', rev 5'CACGCTCAGCTACTTTGTTGAAA3'; Atr, fw 5'TGAAGGACATGTGCATTACCTCATA3', rev 5'ACCAAGGTACATCTGACAGAGTAAGTTT3'; Wnt8a, fw 5'TAACCGGTCCCAAGGCCTA3', rev 5'GCCGCAGTTTTCCAAGTCAC3'; Wnt8b, fw 5'ATACCAGTTTGCTTGGGACCG3', rev 5'CGAAGCCCACGTTGTCACT3'; Wnt9a, fw 5'GGGTCCAGAAGACCCAGACTT3', rev 5'TCTGTGGTGGTCGTGTGACTG3'; Csnk1a1, fw 5'CCTCCATCTTCGCGTCTCAG3', rev 5'ACCGTATGTGAGGGATGCCA; p53, fw 5'GAGATGTTCCGGGAGCTGAAT3', rev 5'TCTGTAGCATGGGCATCCTTTA3'; Ndrg1,fw 5'CACGTATCACGACATCGGCAT3', rev 5'CCACATGGCAGACAGCAAAA3'. Data were collected and analyzed using SDS2.3 software (Applied Biosystems). Relative mRNA abundance after correction for Gapdh control mRNA were quantified using the 2^(-∆∆Ct) method.
Reporter assays
For Wnt signal analysis, cells were transiently transfected with 20 ng pGL4-Top5 firefly luciferase reporter plasmid containing 5 Tcf-responsive elements and a minimal TATA box or a pGL4-Fop5 control plasmid in which Tcf -responsive elements were mutated 48 (provided by Dr. Marc van de Wetering, Hubrecht Institute, Utrecht NL) using Lipofectamine 2000 (Invitrogen). For BMP and TGFβ signal analysis, BRE-luc 49 and (CAGA)12-luc 50 reporters were used following the same procedure (provided by Dr. P. ten Dijke, University Hospital, Leiden NL). Reporter activity was analyzed using a luciferase assay kit (Promega) 72 hours post transfection according to the manufacturer's protocol.
Stable p53 and Csnk1a1 silencing
Cells were transfected using lentiviral TRC shRNA vectors at MOI 1 (LentiExpressTM; Sigma-Aldrich; Dr. Rob Hoeben and Mr Martijn Rabelink, University Hospital, Leiden NL) according to the manufacturers' procedures and bulk-selected in medium containing 1 μg/ml puromycin. The control vector expressed shRNA targeting TurboGFP, and two independent shRNAs targeting mouse p53 or Csnk1a1 were selected from a set of five based on silencing efficiency in bulk puromycin-selected cells.
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